 |
PDBsum entry 5d3e
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Signaling protein
|
PDB id
|
|
|
|
5d3e
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
(+ 0 more)
235 a.a.
|
 |
|
|
|
|
|
|
|
11 a.a.
|
 |
|
|
|
|
|
|
|
11 a.a.
|
 |
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Signaling protein
|
 |
|
Title:
|
 |
Crystal structure of human 14-3-3 gamma in complex with cftr r-domain peptide ps768-ps795
|
|
Structure:
|
 |
14-3-3 protein gamma. Chain: a, b, e, f, i, j. Synonym: protein kinasE C inhibitor protein 1,kcip-1. Engineered: yes. Cystic fibrosis transmembrane conductance regulator. Chain: c, g, k. Fragment: unp residues 762-801. Synonym: cftr,atp-binding cassette sub-family c member 7,channel conductance-controlling atpase,camp-dependent chloride channel.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: ywhag. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Organism_taxid: 9606
|
|
Resolution:
|
 |
|
2.75Å
|
R-factor:
|
0.204
|
R-free:
|
0.244
|
|
|
Authors:
|
 |
L.M.Stevers,S.F.R.Leysen,C.Ottmann
|
|
Key ref:
|
 |
L.M.Stevers
et al.
(2016).
Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR.
Proc Natl Acad Sci U S A,
113,
E1152.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
06-Aug-15
|
Release date:
|
16-Mar-16
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P61981
(1433G_HUMAN) -
14-3-3 protein gamma from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
247 a.a.
235 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains C, G:
E.C.5.6.1.6
- channel-conductance-controlling ATPase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O + closed Cl- channel = ADP + phosphate + open Cl- channel
|
 |
 |
 |
 |
 |
ATP
|
+
|
H2O
|
+
|
closed Cl(-) channel
|
=
|
ADP
|
+
|
phosphate
Bound ligand (Het Group name = )
matches with 50.00% similarity
|
+
|
open Cl(-) channel
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
113:E1152
(2016)
|
|
PubMed id:
|
|
|
|
|
| |
|
Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR.
|
|
L.M.Stevers,
C.V.Lam,
S.F.Leysen,
F.A.Meijer,
D.S.van Scheppingen,
R.M.de Vries,
G.W.Carlile,
L.G.Milroy,
D.Y.Thomas,
L.Brunsveld,
C.Ottmann.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Cystic fibrosis is a fatal genetic disease, most frequently caused by the
retention of the CFTR (cystic fibrosis transmembrane conductance regulator)
mutant protein in the endoplasmic reticulum (ER). The binding of the 14-3-3
protein to the CFTR regulatory (R) domain has been found to enhance CFTR
trafficking to the plasma membrane. To define the mechanism of action of this
protein-protein interaction, we have examined the interaction in vitro. The
disordered multiphosphorylated R domain contains nine different 14-3-3 binding
motifs. Furthermore, the 14-3-3 protein forms a dimer containing two amphipathic
grooves that can potentially bind these phosphorylated motifs. This results in a
number of possible binding mechanisms between these two proteins. Using multiple
biochemical assays and crystal structures, we show that the interaction between
them is governed by two binding sites: The key binding site of CFTR (pS768)
occupies one groove of the 14-3-3 dimer, and a weaker, secondary binding site
occupies the other binding groove. We show that fusicoccin-A, a natural-product
tool compound used in studies of 14-3-3 biology, can stabilize the interaction
between 14-3-3 and CFTR by selectively interacting with a secondary binding
motif of CFTR (pS753). The stabilization of this interaction stimulates the
trafficking of mutant CFTR to the plasma membrane. This definition of the
druggability of the 14-3-3-CFTR interface might offer an approach for cystic
fibrosis therapeutics.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
| |